FINWIRES · TerminalLIVE
FINWIRES

$QURE

16 stories mentioning QUREUpdated 11d ago

Every FINWIRES story that references QURE, newest first.

What's the latest news on QURE?

Sectors

Sector Update: Healthcare Stocks Flat to Higher Premarket Wednesday

Healthcare stocks were flat to higher premarket Wednesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5%.Teva Pharmaceutical Industries (TEVA) shares were up more than 1% after the company said its investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease.Telix Pharmaceuticals (TLX) has completed patient enrollment for the phase 3 study of its commercial PSMA-PET imaging agents Illuccix and Gozellix in prostate cancer imaging in pre-biopsy setting, the company said. Telix Pharmaceuticals stock was up more than 5% pre-bell.uniQure (QURE) has submitted a Biologics License Application to the US Food and Drug Administration for the accelerated approval of AMT-130 to treat Huntington's disease, the company said. uniQure shares were up more than 6% premarket.

$IBB$QURE$TEVA$TLX$XLV
Commodities

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Escalating US-Iran Tensions

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03%, and the actively traded Invesco QQQ Trust (QQQ) retreated 0.2% in Wednesday's premarket activity, as markets traded mixed amid escalating US-Iran tensions.US stock futures were also mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures advancing 0.2%, and Nasdaq futures retreating 0.1% before the start of regular trading.Mortgage applications rebounded by 0.8% in the week ended Aug. 28 despite a further increase in average 30-year fixed mortgage rates, according to Mortgage Bankers Association data released Wednesday.ADP's monthly measure of private payrolls showed a 38,000 increase in August, well below expectations compiled by Bloomberg as of 7:45 am ET for an increase of 47,000 after a 46,000 increase in July.Factory orders data for July will be released at 10:00 am ET, followed by the weekly petroleum stocks data at 10:30 am ET.The Fed's Beige Book, a compilation of economic and business reports from the 12 regional Fed branches, posts at 2 pm ET.In premarket action, bitcoin was down by 0.6%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.2% lower, Ether ETF (EETH) retreated 1.2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.5%, while the Vanguard Industrials Index Fund (VIS) was up 0.8%, and the iShares US Industrials ETF (IYJ) was inactive.FuelCell Energy (FCEL) stock was down more than 12% before the opening bell after the company reported a wider-than-expected fiscal Q3 adjusted loss.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.1%, the iShares US Technology ETF (IYW) was 0.8% lower, and the iShares Expanded Tech Sector ETF (IGM) lost 0.2%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) decreased by 0.1%, while the iShares Semiconductor ETF (SOXX) fell by 0.5%.Dell Technologies (DELL) shares were up 8% after the company posted higher fiscal Q2 adjusted earnings and revenue in addition to lifting its full-year guidance.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.9% lower.Manulife Financial (MFC) shares traded down 4% in early-hours activity after the company said late Tuesday it priced a $750 million public offering in the US of 6.146% subordinated notes due 2041.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.2%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 0.1%, and the iShares US Consumer Staples ETF (IYK) advanced 0.03%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) was 0.3% higher. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was down 0.4%.Nio (NIO) shares were down more than 3% pre-bell after JPMorgan downgraded the company to neutral from overweight.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.5%, the Vanguard Health Care Index Fund (VHT) was down 0.8%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was 0.1% higher.UniQure (QURE) stock was up 3% premarket after the company submitted a Biologics License Application to the US Food and Drug Administration to request accelerated approval of ifezuntirgene inilparvovec, or AMT-130, its investigational gene therapy for Huntington's disease.EnergyThe iShares US Energy ETF (IYE) was down 0.2%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.5% lower.BP (BP) stock was down more than 1% before market open after the company appointed Ian Tyler as board chair.CommoditiesFront-month US West Texas Intermediate crude oil was down by 0.8% to $89.53 per barrel on the New York Mercantile Exchange. Natural gas was up 1.1% at $2.94 per 1 million British Thermal Units. The United States Oil Fund (USO) lost 1.2%, while the United States Natural Gas Fund (UNG) was 0.3% lower.Gold futures for November were down by 0.4% to $4,379.40 an ounce on the Comex. Silver futures retreated 0.6% to $64.96 an ounce. SPDR Gold Shares (GLD) increased 0.1%, and the iShares Silver Trust (SLV) was 0.4% higher.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BP$DELL$EEM$EETH$EXI$FAS$FAZ$FCEL$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MFC$NIO$PMR$QQQ$QURE$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Insider Trading

Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing

Jack Kaye, Director, on June 30, 2026, sold 21,167 shares in Uniqure (QURE) for $983,030. Following the Form 4 filing with the SEC, Kaye has control over a total of 25,996 ordinary shares of the company, with 25,996 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1590560/000090445426000392/xslF345X05/edgar.xml

$QURE
Insider Trading

Uniqure N.v. Insider Sold Shares Worth $9,371,612, According to a Recent SEC Filing

Matthew C Kapusta, Director, Chief Executive Officer, Managing Director, on June 17, 2026, sold 206,100 shares in Uniqure N.v. (QURE) for $9,371,612. Following the Form 4 filing with the SEC, Kapusta has control over a total of 521,795 ordinary shares of the company, with 521,795 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1590560/000090445426000372/xslF345X05/edgar.xml

$QURE
Insider Trading

Uniqure N.v. Insider Sold Shares Worth $526,485, According to a Recent SEC Filing

Madhavan Balachandran, Director, on June 17, 2026, sold 11,685 shares in Uniqure N.v. (QURE) for $526,485. Following the Form 4 filing with the SEC, Balachandran has control over a total of 43,254 ordinary shares of the company, with 43,254 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1590560/000090445426000370/xslF345X05/edgar.xml

$QURE
Wire

UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says

UniQure (QURE) has a clearer path toward possible accelerated approval of its investigational drug for Huntington's disease after the US Food and Drug Administration signaled it is open to accepting a biologics license application based on three-year data, RBC Capital Markets said in a note Wednesday.The investment firm said the regulator will likely accept a BLA with priority review when the company files it in Q3 because of the unmet need.The FDA's willingness to consider the filing without waiting for four-year data and placebo-controlled trial signals regulatory leniency that is also "great news" for the broader industry and improves the outlook for the drug, according to the note.Analysts said they now estimate a 75% chance of approval, compared with 50% previously, although the company still needs to reach alignment with the FDA on the confirmatory trial details prior to BLA submission.RBC has an outperform, speculative risk rating on the stock, with a price target raised to $65 from $35.Shares of uniQure were down more than 2% in Thursday trading.Price: $46.91, Change: $-1.25, Percent Change: -2.60%

$QURE
Sectors

Sector Update: Healthcare Stocks Retreat Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.8%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, ResMed (RMD) shares fell 4.5% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.UniQure (QURE) shares surged 76% after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 0.2%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped almost 11%, and BioNTech was up 2.3%.

$BNTX$MRNA$NVO$QURE$RMD
Wire

Update: UniQure Shares Jump After Plans Announced for FDA BLA Submission for AMT-130 in Huntington's Disease

(Updates with recent stock movement in headline and first paragraph.)UniQure (QURE) shares surged 79% in afternoon trading on Wednesday after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.uniQure said the decision was made after a meeting with the US Food and Drug Administration, during which the regulator said that its three-year analysis from a phase 1/2 study would be acceptable as the primary basis of the application.The FDA also seeks to align with the company on the confirmatory study design before the application is submitted, including consideration of a standard care control group rather than a sham procedure."The consistency and strength of the clinical data generated to date give us great confidence in the product's potential to make a meaningful difference for patients," Chief Executive Matt Kapusta said in a statement.The company expects to receive the final minutes within 30 days of the meeting.Price: $48.35, Change: $+21.36, Percent Change: +79.14%

$QURE
Wire

Top Midday Gainers

AstroNova (ALOT) signed an agreement to be acquired by Arcline Investment Management for $29 per share in an all-cash deal with an enterprise value of about $272 million, it said Wednesday.Shares surged 70% as intraday trading volume jumped to over 1.77 million from a daily average of about 56,000.uniQure's (QURE) shares soared 75% amid heavy trading after the company said Wednesday it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Intraday trading volume climbed to more than 13.8 million from a daily average of roughly 1.75 million.La-Z-Boy's (LZB) reported overnight a year-over-year gain in fiscal Q4 earnings and said it expects sales to outperform the industry in the ongoing quarter.Shares jumped past 19% following an increase in intraday trading volume to over 1.77 million from a daily average of about 413,000.Price: $28.35, Change: $+11.66, Percent Change: +69.88%

$ALOT$LZB$QURE
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.1% higher.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Shares of Novo Nordisk were up more than 3% pre-bell.uniQure (QURE) stock was up more than 66% after the company said it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Jazz Pharmaceuticals (JAZZ) and AbCellera Biologics (ABCL) signed a preclinical research collaboration, option and license deal to discover and develop T-cell engaging multispecific antibodies, the companies said. Shares of AbCellera Biologics were up more than 2% and Jazz Pharmaceuticals stock was over 1% higher premarket.

$ABCL$IBB$JAZZ$NVO$QURE$XLP
Insider Trading

Uniqure Insider Sold Shares Worth $1,127,500, According to a Recent SEC Filing

Walid Abi-Saab, Chief Medical Officer, on May 08, 2026, sold 45,000 shares in Uniqure (QURE) for $1,127,500. Following the Form 4 filing with the SEC, Abi-Saab has control over a total of 169,669 ordinary shares of the company, with 169,669 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1590560/000090445426000260/xslF345X05/edgar.xml

$QURE
Wire

UniQure Shares Fall After Q1 Loss Widens

UniQure (QURE) shares fell 1.8% in early Tuesday trading after the company posted a wider Q1 loss.The company reported a Q1 loss Tuesday of $0.85 per diluted share, widening from a loss of $0.82 a year earlier.Analysts surveyed by FactSet expected a loss of $0.85.Revenue for the quarter ended March 31 was $3.6 million, up from $1.6 million a year earlier.Analysts polled by FactSet expected $5.2 million.Price: $20.30, Change: $-0.38, Percent Change: -1.84%

$QURE
Sectors

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.

$AXSM$LLY$NVO$QURE
Sectors

Sector Update: Health Care

Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.

$QURE
Wire

Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment

(Updates with the latest stock move in the headline and in the first paragraph.)UniQure (QURE) shares were up over 18% in Thursday trading after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 for the treatment of Huntington's disease.The plan came after a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency, it said.The company said it has also been granted a Type B meeting with the US Food and Drug Administration in Q2, and expects to discuss key elements of a potential phase III trial design.The company said it is pursuing additional regulatory pathways in international markets for the potential registration of AMT-130 and expects to provide further updates in H2.Price: $19.82, Change: $+3.09, Percent Change: +18.47%

$QURE
Wire

UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment

UniQure (QURE) said Thursday it plans to submit a UK marketing authorization application in Q3 for AMT-130 for the treatment of Huntington's disease.The decision to submit was made after a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency, the company said.The company said it has also been granted a Type B meeting with the US Food and Drug Administration in Q2, and expects to discuss key elements of a potential phase III trial design and to receive feedback on analysis plan in Q3.The company is actively pursuing additional regulatory pathways in international markets for the potential registration of AMT-130 and expects to provide further updates in H2, it said.Price: $19.02, Change: $+2.29, Percent Change: +13.66%

$QURE

Track with the FINWIRES app suite